ArticleJournal of clinical medicine2026

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.

Suheda Atas Ipek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.